Enhanced Corneal Wound Healing and Neovascularization Suppression via AME-SupraGel: A Biocompatible Hydrogel with Sustained Release and Stability

Le résumé fourni par la source

Amniotic membrane extract (AME) is widely recognized for its anti-inflammatory, antifibrotic, and antiangiogenic properties, making it a valuable option for corneal wound healing. However, short retention time and rapid degradation of AME limit its clinical efficacy. In this study, we developed a novel AME-SupraGel that combines the therapeutic benefits of AME with the sustained-release capabilities of a supramolecular peptide-based hydrogel. The design of AME-SupraGel addresses the limitations of the AME solution by enhancing retention on the ocular surface and providing prolonged therapeutic action. In vitro scratch-wound assays demonstrated significantly faster wound closure in corneal epithelial cells treated with AME-SupraGel than in those treated with AME or the peptide hydrogel alone. Moreover, AME-SupraGel exhibited superior biocompatibility, as evidenced by CCK-8 assays, and achieved sustained release of hepatocyte growth factor over 54 h. In an alkali burn-induced corneal injury model, AME-SupraGel significantly reduced corneal opacity and neovascularization, promoted clearer corneal surfaces, and limited blood vessel formation compared to other treatments. Additionally, the stability of the active components of AME-SupraGel at different temperatures enhances its clinical convenience by facilitating long-term storage without compromising efficacy. Overall, AME-SupraGel represents a promising therapeutic strategy for corneal wound healing, offering a noninvasive, long-lasting, and effective treatment option for ocular surface injuries.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.